- Home
- MPU vs BCAB Comparison
MPU vs BCAB Comparison
Compare MPU & BCAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | MPU | BCAB |
|---|---|---|
| Founded | 1989 | 2007 |
| Country | Singapore | United States |
| Employees | N/A | N/A |
| Industry | Transportation Services | Medicinal Chemicals and Botanical Products |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 65.3M | 71.6M |
| IPO Year | 1998 | 2020 |
Fundamental Metrics
Financial Performance| Metric | MPU | BCAB |
|---|---|---|
| Price | $0.93 | $0.32 |
| Analyst Decision | | Hold |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $1.00 |
| AVG Volume (30 Days) | 136.6K | ★ 2.3M |
| Earning Date | 12-05-2025 | 11-13-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $31,139,100.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 19.98 | N/A |
| 52 Week Low | $0.49 | $0.24 |
| 52 Week High | $4.44 | $1.43 |
Technical Indicators
Market Signals| Indicator | MPU | BCAB |
|---|---|---|
| Relative Strength Index (RSI) | 41.23 | 29.01 |
| Support Level | $0.85 | $0.29 |
| Resistance Level | $0.95 | $0.41 |
| Average True Range (ATR) | 0.09 | 0.10 |
| MACD | -0.01 | -0.03 |
| Stochastic Oscillator | 26.97 | 5.19 |
Price Performance
Historical ComparisonAbout MPU Mega Matrix Corp.
Mega Matrix Inc is a holding company. It operates through its two subsidiaries Mega Metaverse Corp (Mega) and JetFleet Management Corp (JMC). The Company has two business segments which are comprised of : ETH staking business and The leasing of regional aircraft to foreign and domestic regional airlines. The majority of the company's revenue is earned through Leasing business segment. The company operates in USA and Canada, Asia-Pacific, Europe, Middle East and Africa, and Latin America.
About BCAB BioAtla Inc.
BioAtla Inc is a clinical-stage biopharmaceutical company. The company is engaged in the development of a novel class of specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. Its pipeline products comprise mecbotamab vedotin (BA3011), ozuriftamab vedotin (BA3021), and evalstotug (BA3071), and its Phase 1 clinical trial of BA3182 (CAB-EpCAM x CAB-CD3) and Bispecific antibody programs.